Beyond Indication-Based Pricing: Information as a Regulatory Tool for Pharmaceuticals
Adjusting "Willingness-to-Pay" Thresholds based on Disease Severity (Joint with Erik Grönqvist, Per Johansson and August Wadell Leimdörfer)
Upfront Payment vs. Pay-for-Performance for ATMPs in Overlapping Generation Patient Populations